Compare DLTR & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLTR | INSM |
|---|---|---|
| Founded | 1986 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4B | 22.4B |
| IPO Year | 1996 | 2000 |
| Metric | DLTR | INSM |
|---|---|---|
| Price | $128.65 | $127.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 24 |
| Target Price | $123.35 | ★ $201.17 |
| AVG Volume (30 Days) | 2.0M | ★ 3.1M |
| Earning Date | 06-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 144.33 | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $19,411,800,000.00 | N/A |
| Revenue This Year | $8.48 | $182.31 |
| Revenue Next Year | $5.90 | $65.19 |
| P/E Ratio | $73.52 | ★ N/A |
| Revenue Growth | ★ 10.43 | N/A |
| 52 Week Low | $84.71 | $90.39 |
| 52 Week High | $142.40 | $212.75 |
| Indicator | DLTR | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 56.49 | 62.28 |
| Support Level | $117.29 | $95.24 |
| Resistance Level | $132.64 | $140.30 |
| Average True Range (ATR) | 3.05 | 4.89 |
| MACD | -0.39 | 1.80 |
| Stochastic Oscillator | 48.02 | 74.10 |
Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2025, Dollar Tree generated over $19 billion in sales, through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.